mRNA Therapeutics Summit Highlights Breakthroughs in EBV-related Cancer Treatment

Strategic Insights -

The 4th mRNA Therapeutics Summit, held in Boston from July 29-31, 2024, brought together over 400 industry experts and 65 leading researchers to discuss the latest advancements in mRNA technology. Dr. Xiangrong Song, co-founder of WestGene Biopharma, presented key findings on the world's leading EBV-related cancer mRNA therapeutic vaccine, WGc-043. Dr. Song highlighted the vaccine's safety and efficacy in treating NKT cell lymphoma (NKTCL) and nasopharyngeal carcinoma (NPC), showcasing WestGene's proprietary technologies in mRNA sequence design, novel delivery vectors, and scalable manufacturing.

Key Takeaways:

  • Dr. Xiangrong Song, co-founder of WestGene Biopharma, presented the latest research data and technological advancements of WGc-043, the first mRNA therapeutic vaccine targeting EBV-related tumors to achieve IND milestones in both China and the US.
  • WGc-043 demonstrates safety and efficacy in treating NKTCL and NPC, with improved protein expression and delivery system efficiency, while reducing production costs.
  • Dr. Song emphasized the importance of balancing efficacy and safety, a principle that has guided WestGene's R&D efforts from the outset.
  • WestGene's collaborative approach includes pipeline licensing, co-development projects, and technology licensing to accelerate innovation and therapeutic advancements.
  • The Summit featured in-depth discussions on clinical data, platform development, regulatory insights, and frontier applications of mRNA therapeutics for various indications, including oncological, rare, and infectious diseases.

Statistics:

  • Over 400 industry experts and 65 leading researchers attended the 4th mRNA Therapeutics Summit in Boston.
  • WGc-043 has achieved IND milestones in both China and the US, marking a significant breakthrough in EBV-related cancer treatment.
  • Dr. Xiangrong Song presented research covering the development of WGc-043, highlighting its safety and efficacy in treating NKTCL and NPC.

Sources:

  • WestGene